Top Markets
#1 EXOD EXOD +56.80%
#2 MowCat MowCat +48.24%
#3 Glidr Glidr +36.87%
#4 CoW Protocol CoW Protocol +33.98%
#5 Humanity Humanity +28.27%
#6 Codatta Codatta +19.36%
#7 Walrus Walrus +17.42%
#8 Enso Enso +17.35%
#9 The Black Bull The Black Bull +14.68%
#10 Collector Crypt Collector Crypt +14.46%
Coin of the day
EXOD EXOD
Innstillinger
Språk
NORSK
Valuta
USD
Tema
Lysogene S.A. Lysogene S.A.

Lysogene S.A.

LYS
Rangering i aksjer #36618
Lysogene S.A. is a biopharmaceutical firm specializing in gene therapy,... Lysogene S.A. is a biopharmaceutical firm specializing in gene therapy, dedicated to discovering and advancing treatments for children affected by severe neurodegenerative lysosomal storage disorders. Its development pipeline includes LYS-SAF302, which is currently undergoing Phase II/III clinical trials for mucopolysaccharidosis type IIIA (MPS IIIA). Another promising candidate, LYS-GM101, is in Phase I/II development, targeting GM1 gangliosidosis. The company has also forged a research alliance with the Weizmann Institute of Science to pioneer novel adeno-associated virus (AAV) gene therapy approaches for conditions such as neuronopathic Gaucher disease, Parkinson's disease, and other related illnesses. Lysogene S.A. was established in 2009 and is headquartered in Neuilly-sur-Seine, France.
Aksjekurs
$0.30221445
Sist synkronisert: 2023-05-22
Markedsverdi
$2.49M
Endring (1 dag)
-0.10%
Endring (1 år)
0.00%
Land
FR
Handel Lysogene S.A. (LYS)

Kategori

Healthcare
Inntekter for Lysogene S.A. (LYS)
Inntekter i 2026 TTM: 0
Ifølge Lysogene S.A. sine nyeste økonomiske rapporter er selskapets nåværende resultat 0. I 2026 hadde selskapet et resultat på 0, lik resultatet i 2026, som var 0. Resultatet som vises på denne siden er resultat før renter og skatt, eller EBIT.
Inntektshistorikk for Lysogene S.A. fra 2026 til 2026
Inntekter ved slutten av hvert år
År Inntekter Endre
Ikke nok data for de angitte datoene.
Inntekter for lignende selskaper eller konkurrenter
Selskap Inntekter Forskjell i inntekter Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE